Mainz Biomed to hold annual meeting on June 2

Published 02/05/2025, 22:12
Mainz Biomed to hold annual meeting on June 2

Mainz Biomed N.V., a pharmaceutical company specializing in preparations, announced today that it will commence mailing proxy materials for its upcoming annual general meeting. Shareholders of record as of May 5, 2025, will receive the documents, which include a power of attorney and a voting proxy card, starting around May 13, 2025.

The meeting, scheduled for June 2, 2025, will address various corporate matters, as detailed in the attached exhibits to the company’s recent 6-K filing with the U.S. Securities and Exchange Commission (SEC). The exhibits attached are labeled 99.1, 99.2, and 99.3, which consist of the notice for the annual general meeting, the agenda for the meeting, and the voting proxy card and power of attorney, respectively.

In addition to the meeting details, the filing indicates that Mainz Biomed’s current report on Form 6-K, including the aforementioned exhibits, will be incorporated by reference into the company’s Registration Statement on Form F-3 (File No. 333-269091). This suggests that the information may be relevant to investors and the market, as it pertains to the company’s ongoing regulatory disclosures.

The SEC filing, signed by Chief Financial Officer William J. Caragol on May 2, 2025, confirms the company’s compliance with the requirements of the Securities Exchange Act of 1934. Mainz Biomed, headquartered in Mainz, Germany, operates under Dutch law and is listed under the SIC code 2834 for pharmaceutical preparations.

This news is based solely on the company’s SEC filing and serves to inform shareholders and the investing public about the upcoming corporate event. It is important for investors to review these materials carefully to understand the matters to be voted on and to exercise their voting rights in the company’s governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.